Levine M J, Schweitzer P
Division of Cardiology, Department of Medicine, Beth Israel Medical Center, New York, NY, USA.
Vnitr Lek. 2010 Nov;56(11):1138-41.
Atrial fibrillation is the most prevalent clinically relevant arrhythmia; a major cause of morbidity and hospitalization. Additionally, atrial fibrillation carries a significant risk of thrombo-embolic events, specifically cerebrovascular accident. Among the most prevalent risk factors for atrial fibrillation, hypertension not only has the strongest correlation but is also the most prevalent. The renin-angiotensin-aldosterone system represents a prime target for the treatment of hypertension through the use of angiotensin-converting enzymes inhibitors and angiotensin II receptor blockers. In addition to blood pressure control, these medications have been shown to reduce the occurrence of atrial fibrillation. They have been shown to have effects at the cellular level in preventing atrial fibrosis. Additionally, these medications may prevent the development ofatrial fibrillation, reduce the duration of atrial fibrillation, and facilitate electrical cardioversion in patients with the arrhythmia. Therefore, patients with, or at risk for atrial fibrillation may benefit from treatment with renin-angiotensin-aldosterone system antagonists; deriving benefits from these medications beyond simple blood pressure control.
心房颤动是临床上最常见的相关心律失常，是发病和住院的主要原因。此外，心房颤动具有血栓栓塞事件的重大风险，特别是脑血管意外。在心房颤动最常见的危险因素中，高血压不仅相关性最强，而且也是最普遍的。肾素 - 血管紧张素 - 醛固酮系统是通过使用血管紧张素转换酶抑制剂和血管紧张素II受体阻滞剂治疗高血压的主要靶点。除了控制血压外，这些药物已被证明可减少心房颤动的发生。它们已被证明在细胞水平上具有预防心房纤维化的作用。此外，这些药物可能预防心房颤动的发生，缩短心房颤动的持续时间，并促进心律失常患者的电复律。因此，患有心房颤动或有患心房颤动风险的患者可能受益于肾素 - 血管紧张素 - 醛固酮系统拮抗剂的治疗；从这些药物中获得的益处不仅仅是简单的血压控制。
